rs63751011
Positions:
Variant summary
Our verdict is Likely pathogenic. Variant got 7 ACMG points: 8P and 1B. PP5_Very_StrongBP4
The NM_001377265.1(MAPT):c.2091+16C>T variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00000729 in 1,372,328 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★).
Frequency
Genomes: not found (cov: 32)
Exomes 𝑓: 0.0000073 ( 0 hom. )
Consequence
MAPT
NM_001377265.1 intron
NM_001377265.1 intron
Scores
2
Clinical Significance
Conservation
PhyloP100: 2.02
Genes affected
MAPT (HGNC:6893): (microtubule associated protein tau) This gene encodes the microtubule-associated protein tau (MAPT) whose transcript undergoes complex, regulated alternative splicing, giving rise to several mRNA species. MAPT transcripts are differentially expressed in the nervous system, depending on stage of neuronal maturation and neuron type. MAPT gene mutations have been associated with several neurodegenerative disorders such as Alzheimer's disease, Pick's disease, frontotemporal dementia, cortico-basal degeneration and progressive supranuclear palsy. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Likely_pathogenic. Variant got 7 ACMG points.
PP5
Variant 17-46010418-C-T is Pathogenic according to our data. Variant chr17-46010418-C-T is described in ClinVar as [Pathogenic]. Clinvar id is 98222.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr17-46010418-C-T is described in Lovd as [Pathogenic].
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.52). . Strength limited to SUPPORTING due to the PP5.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
MAPT | NM_001377265.1 | c.2091+16C>T | intron_variant | ENST00000262410.10 | NP_001364194.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
MAPT | ENST00000262410.10 | c.2091+16C>T | intron_variant | 1 | NM_001377265.1 | ENSP00000262410 | A2 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD3 genomes
Cov.:
32
GnomAD4 exome AF: 0.00000729 AC: 10AN: 1372328Hom.: 0 Cov.: 25 AF XY: 0.00000441 AC XY: 3AN XY: 679568
GnomAD4 exome
AF:
AC:
10
AN:
1372328
Hom.:
Cov.:
25
AF XY:
AC XY:
3
AN XY:
679568
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome Cov.: 32
GnomAD4 genome
Cov.:
32
Bravo
AF:
ClinVar
Significance: Pathogenic
Submissions summary: Pathogenic:11Other:1
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Frontotemporal dementia Pathogenic:4
Pathogenic, no assertion criteria provided | literature only | OMIM | Oct 01, 2009 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Molecular Genetics, Royal Melbourne Hospital | Apr 05, 2022 | This sequence change in MAPT is an intronic variant located in intron 10. This variant is absent from gnomAD v2.1 and v3.1. This variant is a common Welsh founder mutation and the most common variant in frontotemporal dementia (FTD) cases with British descent (PMID: 19365643). The variant has been reported to segregate with FTD in multiple families (PMID: 9641683). The results from multiple in silico splicing predictors (SpliceAI, MaxEntScan, NNSplice) indicate that this variant may not impact splicing of MAPT. However, RT-PCR and mini-gene assays demonstrated that the variant increases exon 10 RNA expression expected to result in a change in the ratio of tau isoforms of three amino-acid repeats to those of four amino-acid repeats (PMID: 9641683). A transgenic mouse model of the variant also recapitulates the human phenotype and demonstrates much higher levels of four-repeat tau and the adult stage (PMID: 23680655). Based on the classification scheme RMH Modified ACMG Guidelines v1.4.0, this variant is classified as PATHOGENIC. Following criteria are met: PS3, PS4, PP1_Strong, PM2_Supporting, BP4. - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Sep 24, 2023 | This sequence change falls in intron 9 of the MAPT gene. It does not directly change the encoded amino acid sequence of the MAPT protein. This variant is not present in population databases (gnomAD no frequency). This variant has been observed in individual(s) with frontotemporal dementia (PMID: 9641683, 11708988, 11912108, 11971081, 17923640, 19365643, 19766248, 19786698, 20045477, 28097206). It is commonly reported in individuals of Welsh ancestry (PMID: 19365643). This variant is also known as IVS10+16C>T or 10+16C>T. ClinVar contains an entry for this variant (Variation ID: 98222). Algorithms developed to predict the effect of variants on protein structure and function are not available or were not evaluated for this variant. Experimental studies have shown that this variant affects MAPT function (PMID: 9641683, 10329720, 19914360, 23680655, 26136155). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant is not likely to affect RNA splicing. For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Institute of Human Genetics Munich, Klinikum Rechts Der Isar, TU München | Jan 23, 2018 | - - |
not provided Pathogenic:3Other:1
Pathogenic, criteria provided, single submitter | clinical testing | Athena Diagnostics | Apr 04, 2017 | - - |
not provided, no classification provided | literature only | VIB Department of Molecular Genetics, University of Antwerp | - | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Mayo Clinic Laboratories, Mayo Clinic | Jun 16, 2023 | BP4, BP7, PM2 - |
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Jun 12, 2024 | Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis indicates that this variant does not alter splicing; This variant is associated with the following publications: (PMID: 19365643, 27905268, 23885714, 10443890, 7783864, 8940276, 19914360, 26136155, 27082848, 28097206, 29253099, 29930232, 11402146, 25683866, 20045477, 19786698, 18525295, 14755449, 11708988, 11641718, 10446810, 10202939, 9392579, 9088499, 7936288, 11255441, 31031559, 31537715, 9641683, 19884572, 12847166, 15372253, 17923640, 19766248, 11971081, 11971082, 11912108, 31810826, 32804255, 31914217, 10329720, 34561610, 34158384, 37431188, 35790423, 34099697, 23680655, 27594586) - |
Dementia Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Centre for Mendelian Genomics, University Medical Centre Ljubljana | Jan 01, 2017 | - - |
MAPT-related disorder Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Aug 15, 2024 | The MAPT c.1920+16C>T variant is predicted to interfere with splicing. This variant has been reported to be causative for frontotemporal dementia and results in altered splicing based on functional studies (Hutton et al. 1998. PubMed ID: 9641683; Umeda et al. 2013. PubMed ID: 23680655; Wang et al. 2010. PubMed ID: 19914360; Heutink. 2000. PubMed ID: 10767321; Sposito et al. 2015. PubMed ID: 26136155). This variant has not been reported in a large population database, indicating this variant is rare. It is consistently classified as pathogenic in ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/variation/98222/). This variant is interpreted as pathogenic. - |
Memory impairment;C0234985:Mental deterioration;C0338451:Frontotemporal dementia Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Centre for Mendelian Genomics, University Medical Centre Ljubljana | Jan 01, 2017 | - - |
Progressive supranuclear palsy-parkinsonism syndrome Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Victorian Clinical Genetics Services, Murdoch Childrens Research Institute | Oct 19, 2020 | Based on the classification scheme VCGS_Germline_v1.3.3, this variant is classified as Pathogenic. Following criteria are met: 0103 - Loss of function and gain of function are known mechanisms of disease in this gene and are associated with frontotemporal dementia, with or without parkinsonism (MIM#600274), Pick disease (MIM#172700), progressive supranuclear palsy (MIM#601104). Loss of function results in the destabilization of microtubules and loss of tau-partner protein interaction. While gain of function is the increase in fibrillar and/or oligomeric aggregates and microtubules overstabilization (PMID: 26528178). (I) 0107 - This gene is associated with autosomal dominant disease. (I) 0217 - Non-coding variant with known effect. This variant affects the stability of the stem-loop structure within intron 11 resulting in aberrant splicing and increased incorporation of exon 11 (also known as exon 10 in the literature) of MAPT mRNA. The ratio of both isoforms is crucial for proper protein function (PMID: 10329720, 15950767). (SP) 0251 - This variant is heterozygous. (I) 0301 - Variant is absent from gnomAD (both v2 and v3). (SP) 0508 - In silico predictions for abnormal splicing are inconclusive. However, it is important to note that these tools are not optimized for variants beyond the splice region. (I) 0801 - This variant has strong previous evidence of pathogenicity in unrelated individuals. In an international retrospective study of frontotemporal dementia patients, this variant has been reported in 149 individuals from 48 families (PMID: 31810826). (SP) 1208 - Inheritance information for this variant is not currently available in this individual. (I) Legend: (SP) - Supporting pathogenic, (I) - Information, (SB) - Supporting benign - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
CADD
Benign
DANN
Benign
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at